InspireMD, Inc. experienced a slight revenue increase in Q1 2025, reaching $1,529,000, up 1.2% from the previous year. However, the company's net loss widened significantly to $11,166,000, a 58.8% increase, primarily driven by substantial increases in research and development, selling and marketing, and general and administrative expenses. The company continues to face liquidity challenges, with an accumulated deficit and negative operating cash flows, raising substantial doubt about its ability to continue as a going concern.

InspireMD reported Q4 2024 revenue of $1.95 million, up 10.7% year-over-year, driven by expansion into new and existing markets. However, gross profit declined to $469,000 due to higher material and labor costs. Operating expenses surged by 55.8% to $9.84 million, mainly due to increased personnel and regulatory expenses in preparation for the anticipated U.S. launch of CGuard Prime. The company posted a net loss of $9.17 million, or $0.19 per share.

InspireMD announced positive outcomes from the C-GUARDIANS IDE clinical trial and is on track to submit a PMA application to the FDA. Revenue increased by 5.4% to $1,739,000, but gross profit decreased by 32.6% to $331,000. Net loss totaled $7,909,000, or $0.22 per share. The company raised $17.9 million from the full exercise of Series H warrants.

InspireMD reported a 22.0% increase in revenue to $1.51 million for Q1 2024, driven by growth in existing markets. The company sold over 2,500 stents during the quarter, marking a total of over 50,000 stents sold to date. The company is focused on advancing the C-GUARDIANS PMA clinical trial and anticipates potential FDA approval in the first half of 2025.

InspireMD reported a record fourth quarter with a 71.6% increase in revenue compared to the same period last year. The company's growth was driven by CE Mark recertification and increased stent sales. InspireMD also announced positive data from its C-GUARDIANS clinical trial and advancements in its product pipeline.

InspireMD reported an 8.7% increase in revenue for Q3 2023, driven by CGuard EPS sales, and highlighted positive safety data from the C-GUARDIANS U.S. IDE clinical trial. The company also noted the expansion of CAS coverage by CMS as a positive development.

InspireMD reported a 7.7% increase in revenue to $1.649 million for Q2 2023, driven by a 9.6% increase in CGuard EPS sales. The company completed a private placement for up to $113.6 million and enrollment in the C-Guardians US IDE trial.

InspireMD reported a 4.7% increase in revenue to $1.239 million for Q1 2023, driven by a 6.7% increase in CGuard EPS sales. The company also completed a transformational private placement for up to $113.6 million, including $42.2 million upfront. The company's CE mark was reinstated under the MDD directive allowing the company to resume sales and shipments to the EU countries.

InspireMD reported a decrease in total revenue for Q4 2022, primarily due to the temporary expiration of the CE Mark, which impacted sales in EU countries. The company is progressing with its U.S. IDE trial and anticipates CE Mark recertification. Total revenue decreased to $1,026,000 from $1,380,000 during the fourth quarter of 2021. Net loss for the fourth quarter of 2022 totaled $4,845,000, or $0.60 per basic and diluted share, compared to a net loss of $4,097,000, or $0.53 per basic and diluted share, for the same period in 2021.

InspireMD reported a 33.6% increase in total revenue for Q3 2022, driven by strong CGuard EPS sales growth. The company is progressing with its C-Guardian US IDE trial and anticipates full enrollment by the end of Q1 2023. However, the net loss increased compared to the same period in 2021.

InspireMD reported a 47.6% increase in total revenue for the second quarter of 2022, driven by a 47.8% increase in CGuard EPS sales volume. The company is progressing with its U.S. IDE trial and anticipates full enrollment by approximately Q1 of next year.

InspireMD reported a 17.6% increase in revenue for Q1 2022, driven by a 19.8% increase in CGuard EPS sales volume. The company's net loss increased due to higher operating expenses related to the C-Guardians FDA study and share-based compensation. The company continues to expand its delivery systems around CGuard and expects to launch innovative delivery solutions in early 2023.

InspireMD reported a significant increase in revenue for Q4 2021, driven by strong growth in CGuard EPS sales. The company's gross profit improved compared to the previous year. Operating expenses also increased due to investments in a U.S. FDA study and market expansion.

InspireMD reported a 9.3% increase in revenue to $1.071 million for Q3 2021, driven by a 23.8% increase in CGuard EPS sales volume. The company's net loss totaled $4.071 million, or $0.53 per share, compared to a net loss of $2.233 million, or $0.96 per share, for the same period in 2020. Cash, cash equivalents, and short-term bank deposits were $37.1 million as of September 30, 2021.

InspireMD reported a significant revenue increase of 231.6% in Q2 2021, driven by a strong rebound in CGuard EPS sales. The company also made progress in its U.S. expansion efforts and product pipeline development.

InspireMD reported a slight decrease in revenue for Q1 2021, with CGuard revenue remaining stable but MGuard Prime EPS revenue declining. Gross profit decreased significantly due to increased write-offs, and operating expenses increased due to higher salary, share-based compensation, and development expenses. The company's net loss increased compared to the same period in 2020, but cash and cash equivalents increased significantly due to equity transactions.

InspireMD reported a significant decrease in revenue for Q4 2020, primarily due to a litigation settlement and the impact of COVID-19 on procedure volumes. Gross profit also declined significantly. However, the company highlighted progress in strategic initiatives, including IDE approval in the US and expansion in Latin America and China, and improved its cash position through public offerings.

InspireMD reported a revenue increase of 4.4% to $980,000 for the third quarter of 2020, compared to $939,000 in the same period of 2019. The increase was driven by a 69.0% increase in sales volume of MGuard EPS, offset by a 2.2% decrease in sales volume of CGuard Prime EPS. Gross profit increased by 132.8% to $298,000, and the net loss totaled $2,233,000, or $0.06 per basic and diluted share.

InspireMD's Q2 2020 revenue decreased by 76.9% to $313,000 compared to $1,354,000 in Q2 2019, primarily due to the postponement of elective procedures during the COVID-19 pandemic, resulting in a net loss of $2,480,000, or $0.20 per share.

InspireMD reported a significant increase in revenue for Q1 2020, driven by strong sales of its CGuard EPS product. The company also improved its gross profit and reduced operating expenses, leading to a lower net loss compared to the same period in the previous year.

InspireMD reported a 23.2% increase in revenue for Q4 2019, driven by a 31.4% increase in CGuard EPS sales. However, this was partially offset by a decrease in MGuard Prime EPS sales and an increase in operating expenses, resulting in a net loss of $2,557,000, or $0.57 per share.